

PEI Pharmacare Bulletin

Issue (2022 - 1)

January 10, 2022

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY
(EFFECTIVE DATE: (JANUARY 10, 2022))

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN/PDIN	MFR
Dabrafenib	Tafinlar	50 mg	Capsule	02409607	NRV
	Tafinlar	75 mg	Capsule	02409615	
Criteria	<p>In addition to currently listed criteria, the indication of adjuvant melanoma has been added with the following criteria; In combination with trametinib for the adjuvant treatment of patients with cutaneous melanoma who meet all of the following criteria:</p> <ul style="list-style-type: none"> • Stage IIIA (limited to lymph node metastases of greater than 1 mm) to stage IIID disease (AJCC 8th edition) • BRAF V600-mutation positive • Completely resected disease including in-transit metastases <p>Clinical Notes:</p> <ol style="list-style-type: none"> 1. Patients must have a good performance status. 2. Treatment should continue until disease recurrence, unacceptable toxicity, or up to a maximum of 12 months. <p>Claim Notes:</p> <ol style="list-style-type: none"> 1. Requests will be considered for patients with regional lymph nodes with micrometastases after sentinel lymph node biopsy. 2. Requests will not be considered for patients who received adjuvant immunotherapy for greater than three months. Patients may switch to BRAF targeted therapy within the first three months of initiating immunotherapy to complete a total of 12 months of adjuvant treatment. 3. Approval period: up to 12 months 				

Program Eligibility	High Cost Drug Program, Catastrophic Drug Program				
Trametinib	Mekinist Mekinist	0.5 mg 2 mg	Tablet Tablet	02409623 02409658	NVR
Criteria	<p>In addition to currently listed criteria, the indication of adjuvant melanoma has been added with the following criteria; In combination with dabrafenib for the adjuvant treatment of patients with cutaneous melanoma who meet all of the following criteria:</p> <ul style="list-style-type: none"> • Stage IIIA (limited to lymph node metastases of greater than 1 mm) to stage IIID disease (AJCC 8th edition) • BRAF V600-mutation positive • Completely resected disease including in-transit metastases <p>Clinical Notes:</p> <ol style="list-style-type: none"> 1. Patients must have a good performance status. 2. Treatment should continue until disease recurrence, unacceptable toxicity, or up to a maximum of 12 months. <p>Claim Notes:</p> <ol style="list-style-type: none"> 1. Requests will be considered for patients with regional lymph nodes with micrometastases after sentinel lymph node biopsy. 2. Requests will not be considered for patients who received adjuvant immunotherapy for greater than three months. Patients may switch to BRAF targeted therapy within the first three months of initiating immunotherapy to complete a total of 12 months of adjuvant treatment. 3. Approval period: up to 12 months 				
Program Eligibility	High Cost Drug Program, Catastrophic Drug Program				